Focused ultrasound with anti-pGlu3 Aβ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells
Tao Sun,Qiaoqiao Shi,Yongzhi Zhang,Chanikarn Power,Camilla Hoesch,Shawna Antonelli,Maren K Schroeder,Barbara J Caldarone,Nadine Taudte,Mathias Schenk,Thore Hettmann,Stephan Schilling,Nathan J McDannold,Cynthia A Lemere,Maren K. Schroeder,Barbara J. Caldarone,Nathan J. McDannold,Cynthia A. Lemere
DOI: https://doi.org/10.1016/j.jconrel.2021.06.037
IF: 11.467
2021-08-01
Journal of Controlled Release
Abstract:<p>Pyroglutamate-3 amyloid-β (pGlu3 Aβ) is an N-terminally modified, pathogenic form of amyloid-β that is present in cerebral amyloid plaques and vascular deposits. Here, for the first time, wee used focused ultrasound (FUS) with microbubbles to enhance the intravenous delivery of an Fc-competent anti-pGlu3 Aβ monoclonal antibody, 07/2a mAb, across the blood brain barrier (BBB) in an attempt to improve Aβ removal and memory in aged APP/PS1dE9 mice, an Alzheimer's disease-like model of amyloidogenesis.</p><p>First, we demonstrated that bilateral hippocampal FUS-BBBD led to a 5.5-fold increase of 07/2a mAb in the brains of sonicated aged APP/PS1dE9 mice compared to non-sonicated mice 72 h following a single treatment. Then, we determined that three weekly treatments with 07/2a mAb alone improved spatial learning and memory in aged, plaque-rich APP/PS1dE9 mice, and that this improvement occurred faster and in a higher percentage of animals when combined with FUS-BBBD. APP/PS1dE9 mice given the combination treatment had reduced hippocampal plaque burden compared to PBS-treated APP/PS1dE9 mice. Furthermore, synaptic protein levels were higher in hippocampal synaptosomes from APP/PS1 mice given the combination treatment compared to sham controls, and there were more CA3 synaptic puncta labeled in the APP/PS1dE9 mice given the combination treatment compared to those given mAb alone. Plaque-associated microglia were present in the hippocampi of APP/PS1dE9 mice treated with 07/2a mAb with and without FUS-BBBD. However, we discovered that plaque-associated Ly6G+ monocytes were only present in the hippocampi of APP/PS1dE9 mice that were given FUS-BBBD alone or even more so, the combination treatment. Lastly, FUS- BBBD did not increase the incidence of microhemorrhage in mice with or without 07/2a mAb treatment.</p><p>Our findings suggest that FUS is a useful tool to enhance delivery and efficacy of an anti-pGlu3 Aβ mAb for immunotherapy either via an additive effect or an independent mechanism. We revealed a potential novel mechanism wherein the combination of 07/2a mAb with FUS-BBBD led to greater monocyte infiltration and recruitment to plaques in this AD-like model. Overall, these effects resulted in greater plaque removal, sparing of synapses and improved cognitive function without causing overt damage, suggesting the possibility of FUS-BBBD as a noninvasive method to increase the therapeutic efficacy of drugs or biologics in AD patients.</p>
pharmacology & pharmacy,chemistry, multidisciplinary